Clinical Trial: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

U.S., June 28 -- ClinicalTrials.gov registry received information related to the study (NCT07041099) titled 'A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease' on June 18.

Brief Summary: A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Study Start Date: Sept. 15, 2025

Study Type: INTERVENTIONAL

Condition: Sjogren Sjogren Disease Sjogren's Syndrome

Intervention: DRUG: CLN-978

Specified dose on specified days

Recruitment Status: RECRUITING

Sponsor: Cullinan Therapeutics Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....